A comparison of three feedlot vaccination programs on the health, growth performance, and carcass characteristics of high-risk heifers procured from auction markets
Keywords:bovine respiratory disease, BRD, vaccines, pathogen, antigens, health, growth performance, feedlot cattle
Mannheimia haemolytica (MH) is the primary bacterium involved with bovine respiratory disease (BRO), and there are differences between how the vaccines which confer immunity against this important pathogen are manufactured. Generally speaking, the bacterin and toxoid components of commercially available MH vaccines are harvested through propagation of whole-cell MH cultures. Nuplura® PH (NUP; Elanco Animal Health, Greenfield, IN) contains both toxoid and cell-associated antigens, but these antigens differ as they are manufactured using recombinant technology and a proprietary purification process. The relative efficacy of vaccine programs incorporating NUP versus products derived from whole-cell MH culture has not been evaluated in a large-pen feedlot setting. The objective of this study was to compare 3 vaccination programs on the health, growth performance, and carcass characteristics of feedlot heifers.